Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Dermatologic 1Breast 1

Conditions

Breast Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Neoplasms 1Melanoma 1Liver Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 61Cisplatin 45Cetuximab 32Radiotherapy 25Nivolumab 22Docetaxel 16Radiotherapy, Intensity-Modulated 14Paclitaxel 13Carboplatin 13durvalumab 11Radiation 10Fluorouracil 10Magnetic Resonance Spectroscopy 9Cyclophosphamide 9fludarabine 8Erlotinib Hydrochloride 8budigalimab 7Ipilimumab 7atezolizumab 6Radiosurgery 6Gemcitabine 6Drug Therapy 6130-nm albumin-bound paclitaxel 6tremelimumab 5tislelizumab 5spartalizumab 5fludarabine phosphate 5avelumab 5Surgical Procedures, Operative 5Specimen Handling 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Squamous Cell Carcinoma of Head and Neck × C188-9 compound × Clear all
NCT03195699 2025-03-21

Oral STAT3 Inhibitor, TTI-101, in Patients With Advanced Cancers

Tvardi Therapeutics, Incorporated

Phase 1 Completed
64 enrolled
BreastDermatologicGastrointestinalHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Liver Neoplasms, Melanoma, Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡